The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
Abstract
Objective: CD40–CD40 ligand (CD40L) interactions play a significant role in the production of autoantibodies and tissue injury in lupus nephritis. We performed an open‐label, multiple‐dose study to evaluate the safety, efficacy, and pharmacokinetics of BG9588, a humanized anti‐CD40L antibody, in patients with proliferative lupus nephritis. The primary outcome measure was 50% reduction in proteinuria without worsening of renal function. Methods: Twenty‐eight patients with active proliferative lupus nephritis were scheduled to receive 20 mg/kg of BG9588 at biweekly intervals for the first 3 doses and at monthly intervals for 4 additional doses. Safety evaluations were performed on all patients. Eighteen patients receiving at least 3 doses were evaluated for efficacy. Results: The study was terminated prematurely because of thromboembolic events occurring in patients in this and other BG9588 protocols (2 myocardial infarctions in this study). Of the 18 patients for whom efficacy could be evaluated, 2 had a 50% reduction in proteinuria without worsening of renal function. Mean reductions of 38.9% (P < 0.005), 50.1% (P < 0.005), and 25.3% (P < 0.05) in anti–double‐stranded DNA (anti‐dsDNA) antibody titers were observed at 1, 2, and 3 months, respectively, after the last treatment. There was a significant increase in serum C3 concentrations at 1 month after the last dose (P < 0.005), and hematuria disappeared in all 5 patients with significant hematuria at baseline. There were no statistically significant reductions in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concentrations after therapy. Conclusion: A short course of BG9588 treatment in patients with proliferative lupus nephritis reduces anti‐dsDNA antibodies, increases C3 concentrations, and decreases hematuria, suggesting that the drug has immunomodulatory action. Additional studies will be needed to evaluate its long‐term effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Self-citationEfficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Kirk, A. D., Burkly, L. C., Batty, D. S., Baumgartner, R. E., Berning, J. D., Buchanan, K., Fechner, J. H., Germond, R. L., Kampen, R. L., Patterson, N. B., et al. (1999) · Nature Medicine · doi:10.1038/9536 · Cited by 826
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Self-citationAruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L. S., Stenkamp, R., Neubauer, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90668-g · Cited by 814
CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism
André, P., Prasad, K. S. S., Denis, C. V., He, M., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 726
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM
Korthäuer, U., Graf, D., Mages, H. W., Brière, F., Padayachee, M., Malcolm, S., Ugazio, A. G., Notarangelo, L. D., Levinsky, R. J., & Kroczek, R. A. (1993) · Nature · doi:10.1038/361539a0 · Cited by 721
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H., & Cosimi, A. B. (2000) · Nature Medicine · doi:10.1038/72162 · Cited by 692
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Self-citationDesai-Mehta, A., Lu, L., Ramsey-Goldman, R., & Datta, S. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118643 · Cited by 517
Boumpas, D. T., Austin, H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00003 · Cited by 500
Self-citationIllei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
Self-citationA Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis
Lewis, E. J., Hunsicker, L. G., Lan, S.-P., Rohde, R. D., & Lachin, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205213262101 · Cited by 473
Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.
Mohan, C., Shi, Y., Laman, J. D., & Datta, S. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1470 · Cited by 364
Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.
Koshy, M., Berger, D., & Crow, M. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118855 · Cited by 359
Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.
Balomenos, D., Rumold, R., & Theofilopoulos, A. N. (1998) · Journal of Clinical Investigation · doi:10.1172/jci750 · Cited by 356
Steinberg, A. D., & Steinberg, S. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340803 · Cited by 348
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Illei, G. G., Takada, K., Parkin, D., Austin, H. A., Crane, M., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Pando, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10142 · Cited by 329
Self-citationBoumpas, D. T., Austin, H. A., Fessler, B. J., Balow, J. E., Klippel, J. H., & Lockshin, M. D. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00009 · Cited by 303
Self-citationFunctional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals.
Yellin, M. J., Brett, J., Baum, D., Matsushima, A., Szabolcs, M., Stern, D., & Chess, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1857 · Cited by 273
“Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis
Moroni, G., Quaglini, S., Maccario, M., Banfi, G., & Ponticelli, C. (1996) · Kidney International · doi:10.1038/ki.1996.528 · Cited by 267
Belmont, H. M., Abramson, S. B., & Lie, J. T. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390103 · Cited by 253
Traynor, A. E., Schroeder, J., Rosa, R. M., Cheng, D., Stefka, J., Mujais, S., Baker, S., & Burt, R. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02627-1 · Cited by 245
Brodsky, R. A., Petri, M., Smith, B. D., Seifter, E. J., Spivak, J. L., Styler, M., Dang, C. V., Brodsky, I., & Jones, R. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00007 · Cited by 236
Renal Involvement in Systemic Lupus Erythematosus: A Study of 180 Patients from a Single Center
Du Le Huong, T., Papo, T., Beaufils, H., Wechsler, B., Blétry, O., Baumelou, A., Godeau, P., & Piette, J.-C. (1999) · Medicine · doi:10.1097/00005792-199905000-00002 · Cited by 233
Felson, D. T., & Anderson, J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412133112402 · Cited by 233
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
Ioannidis, J. P. A., Boki, K. A., Katsorida, M. E., Drosos, A. A., Skopouli, F. N., Boletis, J. N., & Moutsopoulos, H. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00832.x · Cited by 231
Mycophenolate Mofetil Therapy in Lupus Nephritis: Clinical Observations
DOOLEY, M. A., COSIO, F. G., NACHMAN, P. H., FALKENHAIN, M. E., HOGAN, S. L., FALK, R. J., & HEBERT, L. A. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v104833 · Cited by 230
Yellin, M. J., Winikoff, S., Fortune, S. M., Baum, D., Crow, M. K., Lederman, S., & Chess, L. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.58.2.209 · Cited by 228
Early, G. S., Zhao, W., & Burns, C. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.3159 · Cited by 218
Daikh, D. I., Finck, B. K., Linsley, P. S., Hollenbaugh, D., & Wofsy, D. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3104 · Cited by 217
Kalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2158 · Cited by 199
The soluble CD40 ligand sCD154 in systemic lupus erythematosus
Kato, K., Santana-Sahagún, E., Rassenti, L. Z., Weisman, M. H., Tamura, N., Kobayashi, S., Hashimoto, H., & Kipps, T. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7014 · Cited by 196
The very long-term prognosis and complications of lupus nephritis and its treatment
Bono, L. (1999) · QJM · doi:10.1093/qjmed/92.4.211 · Cited by 172
Jo Berden, H. M. (1997) · Kidney International · doi:10.1038/ki.1997.365 · Cited by 170
The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus
Huang, W., Sinha, J., Newman, J., Reddy, B., Budhai, L., Furie, R., Vaishnaw, A., & Davidson, A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10273 · Cited by 165
Self-citationTreatment of murine lupus with cDNA encoding IFN-γR/Fc
Lawson, B. R., Prud’homme, G. J., Chang, Y., Gardner, H. A., Kuan, J., Kono, D. H., & Theofilopoulos, A. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10167 · Cited by 158
Clark, U. B., Foy, T. M., & Noelle, R. J. (1996) · Advances in immunology · doi:10.1016/s0065-2776(08)60854-8 · Cited by 153
Yellin, M. J., D’Agati, V. D., Parkinson, G., Han, A. S., Szema, A. M., Baum, D., Estes, D., Szabolcs, M. J., & Chess, L. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400117 · Cited by 153
Davis, J. C., Totoritis, M. C., Rosenberg, J., Sklenar, T. A., & Wofsy, D. (2001) · PubMed · Cited by 146
Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney
van Kooten, C., Gerritsma, J. S. J., Paape, M. E., van Es, L. A., Banchereau, J., & Daha, M. R. (1997) · Kidney International · doi:10.1038/ki.1997.102 · Cited by 115
Karmann, K., Min, W., Fanslow, W. C., & Pober, J. S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.1.173 · Cited by 114
Outcome criteria for lupus nephritis trials: A critical overview
Boumpas, D. T., & Balow, J. E. (1998) · Lupus · doi:10.1191/096120398678920758 · Cited by 94
Self-citationKuroiwa, T., Schlimgen, R., Illei, G. G., McInnes, I. B., & Boumpas, D. T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.3323 · Cited by 90
Self-citationThe Prognosis of Lupus Nephritis in African-Americans: A Retrospective Analysis
Bakir, A. A., Levy, P. S., & Dunea, G. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80177-6 · Cited by 89
Grammer, A. C., & Lipsky, P. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10287 · Cited by 62
Kuroiwa, T., Lee, E. G., Danning, C. L., Illei, G. G., McInnes, I. B., & Boumpas, D. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.2168 · Cited by 57
Self-citationKuroiwa, T., Lee, E. G., Danning, C. L., Illei, G. G., McInnes, I. B., & Boumpas, D. T. (1999) · PubMed · Cited by 56
Self-citationResponse to treatment as a predictor of longterm outcome in patients with lupus nephritis.
Fraenkel, L., MacKenzie, T. A., Joseph, L., Kashgarian, M. J., Hayslett, J. P., & Esdaile, J. M. (1994) · PubMed · Cited by 55
Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis
Biancone, L., Andres, G. A., Ahn, H., DeMartino, C., & Stamenkovic, I. (1995) · Kidney International · doi:10.1038/ki.1995.314 · Cited by 53
Clinical evaluation and monitoring of lupus kidney disease
Austin, H. A. (1998) · Lupus · doi:10.1191/096120398678920749 · Cited by 48
Significance of IgA antiphospholipid antibodies
Wilson, W., Faghiri, Z., Taheri, F. H., & Gharavi, A. E. (1998) · Lupus · doi:10.1177/096120339800700225 · Cited by 39
Hydroxychloroquine: past, present, future
Petri, M. (1998) · Lupus · doi:10.1191/096120398678919886 · Cited by 35
Funakoshi, S., Taub, D. D., Anver, M. R., Raziuddin, A., Asai, O., Reddy, V. S., Rager, H., Fanslow, W. C., Longo, D. L., & Murphy, W. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119183 · Cited by 26
Long-term remission with allogenic bone marrow transplantation in systemic lupus erythematosus
Gur-Lavi, M. (1999) · Arthritis & Rheumatism · Cited by 25
New prospects for treatment of lupus nephritis.
Balow, J. E., Boumpas, D. T., & Austin, H. A. (2000) · PubMed · Cited by 19
Self-citation
Cited by
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
CD40/CD154 Interactions at the Interface of Tolerance and Immunity
Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104533 · Cited by 683
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Immune and Inflammatory Role in Renal Disease
Imig, J. D., & Ryan, M. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120028 · Cited by 356
Metadata
- Authors
- Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-02-28
- Volume
- 48
- Issue
- 3
- Pages
- 719-727
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2029957805
- Cited by
- 618
- References
- 61
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.